Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment.

Al Mahtab, Mamun; Akbar, Sheikh Mohammad Fazle; Aguilar, Julio Cesar; Yoshida, Osamu; Khan, Sakirul; Gerardo, Guillen Nieto; Hiasa, Yoichi

Al Mahtab, Mamun; Akbar, Sheikh Mohammad Fazle; Aguilar, Julio Cesar; Yoshida, Osamu; Khan, Sakirul; Gerardo, Guillen Nieto; Hiasa, Yoichi.

Afiliação

Al Mahtab M; Department of Hepatology, Interventional Hepatology Division, Bangabandhu Sheikh Mujib Medical University, BSMMU, Dhaka, Bangladesh.
Akbar SMF; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Aguilar JC; Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Yoshida O; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Khan S; Department of Microbiology, Faculty of Medicine, Oita University, Oita, Japan.
Gerardo GN; Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.

Front Med (Lausanne) ; 10: 1032531, 2023.

Article em En | MEDLINE | ID: mdl-36844221

Palavras-chave

5-year follow-up; NASVAC; chronic hepatitis B; immune therapy; nasal therapeutic vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bangladesh

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google